Autres langues AbClon Inc.

Actions

A174900

KR7174900001

Produits pharmaceutiques

Cours en clôture Korea S.E. 30/09/2026			Varia. 5j.	Varia. 1 janv.
22 350,00 ^KRW	+2,76%		+16,29%	-47,41%

08/06	Henlius, partenaire d'Alligator, administre les premières doses dans le cadre de l'étude sur le HLX22	FW
22/05	Alligator Bioscience commente la mise à jour de Henlius concernant le HLX22	FW

Autres langues

21/09	AbClon Inc.(KOSDAQ:A174900) added to S&P Global BMI Index
08/06	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22
22/05	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22
23/04	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026
23/04	Alligator Bioscience Announces Preclinical Data Presentation of Hlx49 Antibody?Drug Conjugate
07/04	Abclon wins 396 million won order
09/03	AbClon wins 778 million won order
02/03	Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22
01/10/25	AbClon Inc. announced that it expects to receive KRW 35.999952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture Capital and other investors.
27/08/25	Abclon wins 309 million won order
20/05/25	Abclon Wins 354 Million Won Order
19/05/25	AbClon Inc To Issue 1.4 Million Common Shares
19/05/25	AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.
15/05/25	Abclon Wins 307 Million Won Order
09/05/25	AbClon Inc. announced that it expects to receive KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.
02/04/25	AbClon Inc.(KOSDAQ:A174900) dropped from S&P Global BMI Index
04/12/24	Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial
21/05/24	Alligator Bioscience’s Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer
12/05/23	AbClon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
17/04/23	AbClon Presents Non-Clon and Phase 1 Interim Results of its AT101 Novel CAR-T Therapy at the Annual 2023 AACR Conference
08/11/22	Alligator Bioscience Announces IND Approval for Second Phase 2 Clinical Trial of AC101 (HLX22) in Gastric Cancer developed by Shanghai Henlius Biotech in China
28/09/22	AbClon Inc. announced that it has received KRW 11.999976975 billion in funding from Quad Investment Management Corp.
28/07/22	AbClon Inc. announced that it has received KRW 10 billion in funding from Quad Investment Management Corp.
26/07/22	AbClon Inc. announced that it expects to receive KRW 11.999976975 billion in funding from Quad Investment Management Corp.
26/07/22	AbClon Inc. announced that it expects to receive KRW 10 billion in funding from Quad Investment Management Corp.